订阅小程序
旧版功能

Multicentre, 26-Week, Open-Label Phase 2 Trial of the JAK Inhibitor Filgotinib in Behçet’s Disease, Idiopathic Inflammatory Myopathies and IgG4-related Disease: DRIMID Study Protocol

Bettina C Geertsema-Hoeve, Jan A M van Laar,Joost Raaphorst, Sander W Tas,Paco M J Welsing,Robbert J Goekoop, Cesar Magro Checa,Rogier M Thurlings, Nicolle H Rekers, Erik Present, Jacob M van Laar

BMJ open（2025）

引用 0|浏览2
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要